Management Team


Robert Booth PhD
Founder and Chief Executive Officer

Robert Booth PhD
Chief Executive Officer, Virobay

Robert F. Booth, Ph.D. has served as our Chief Executive Officer, President, Secretary and a member of our board of directors since May 2010 and he was previously our Executive Chairman and a member of our board of directors from July 2006 to May 2010. From July 2006 to May 2010, Dr. Booth served as an Operating Partner and Senior Advisor at TPG Biotechnology Partners, LP, a venture capital company. From December 2006 to July 2007, Dr. Booth served as the acting Chief Scientific Officer of Galleon Pharmaceuticals, Inc., a company which is developing new therapeutics for diseases of the respiratory system. From 2002 to 2006, Dr. Booth was the Chief Scientific Officer at Celera Genomics Corporation, or Celera, a drug discovery and development company. Dr. Booth served as Senior Vice President at Roche Bioscience, a part of F. Hoffmann-La Roche Ltd, or Roche, from 1996 to 2002, where he was responsible for research and early development activities in the therapeutic areas of inflammation, autoimmunity, respiratory diseases, transplantation, bone diseases and viral diseases. Dr. Booth was a member of the Global Research Management Team and a member of the Business Development Committee, which oversaw licensing opportunities for Roche. From 1989 to December 1995, Dr. Booth served as Director of Biology for Roche Products Ltd, a part of Roche’s research operation, which was located in the United Kingdom. Dr. Booth currently serves on the boards of directors of Pharmacyclics, Inc., Galleon Pharmaceuticals, Inc. and Glialogix, Inc., and is Chairman of the Scientific Advisory Board at Galleon Pharmaceuticals, Inc. Dr. Booth also serves as a member of the Scientific Advisory Boards of ShangPharma Corporation, Elcelyx Therapeutics, Inc. and NaZura Biohealth, Inc. Dr. Booth received a B.Sc. and a Ph.D. from the University of London in biochemistry.

Kyle Elrod
Senior Vice President, Project Management and Operations

Kyle Elrod
Senior Vice President, Project Management and Operations

Kyle C. Elrod has served as our Senior Vice President of Project Management and Operations since June 2014. From March 2012 to June 2014, Mr. Elrod served as our Vice President of Project Management and Operations. From January 2010 to March 2012, Mr. Elrod served as a Research & Development Leader and Product Manager at Life Technologies Corporation, where he oversaw the SOLiD next generation genomic sequencing platform. From June 2006 to January 2010, Mr. Elrod served as our Vice President of Project Management and was responsible for overseeing our initial new drug filings. From January 1994 to May 2006, Mr. Elrod served in several positions in the field of project management, including the Director of Research and Development Projects at Celera, where he was the project manager for all of Celera’s preclinical and clinical programs. Mr. Elrod received a B.A. in immunology and microbiology from University of California, Berkeley.

Leslie Holsinger PhD
Vice President, Biology

Leslie Holsinger PhD
Vice President, Biology

Leslie J. Holsinger, Ph.D. has served as our Vice President of Biology since October 2010. From July 2006 to September 2010, Dr. Holsinger served as our Director of Biology. From November 2003 to June 2006, Dr. Holsinger served as Associate Director of Cell Biology at Celera, where she was responsible for translational and discovery biology. From December 1997 to August 2003, Dr. Holsinger served as Group Leader in discovery research at Sugen, Inc., a Pfizer company, where she assisted in drug discovery programs focused on kinase and phosphatase inhibitor drug development in multiple therapeutic areas. Dr. Holsinger received a B.A. in biochemistry from Occidental College and a Ph.D. in molecular and cellular biology from Northwestern University. She also completed post-doctoral studies at Stanford University School of Medicine.

Anantha Sudhakar PhD MBA
Vice President, Chemistry, Manufacturing and Controls

Anantha Sudhakar PhD MBA
Vice President, Chemistry, Manufacturing and Controls

Anantha R. Sudhakar, Ph.D. has served as our Vice President of Chemistry and Manufacturing and Controls, or CMC, since June 2012. From December 2009 to June 2012, Dr. Sudhakar served as Senior Director of CMC at Achaogen, Inc., where he was responsible for the process research, formulation development and manufacturing of both active pharmaceutical ingredients, or API, and drug products, or DP. From May 2006 to December 2009, Dr. Sudhakar served as Senior Director of CMC at Sunesis Pharmaceuticals, Inc., an emerging pharmaceutical company, where he was responsible for all CMC activities related to API and DP development. From July 2004 to May 2006, Dr. Sudhakar was Senior Director, Process Chemistry at Celera Genomics where he was responsible for API process research and manufacturing. From October 1989 to July 2004, Dr. Sudhakar served in several capacities at Schering Plough Corporation, including Senior Scientist and Associate Director, where he developed commercial processes for multiple drugs. Dr. Sudhakar received a M.Sc. in Chemistry from Indian Institute of Technology, Chennai, India, an M.B.A. in finance and management from New York University Stern School of Business and a Ph.D. in organic chemistry from Columbia University. He also completed post-doctoral studies at University of Wisconsin-Madison and Stanford University.

Elizabeth Shigezumi MPA
Clinical Trial Manager, Clinical Operations

Elizabeth Shigezumi MPA
Clinical Trial Manager, Clinical Operations

Elizabeth G. Shigezumi has served as our Clinical Trial Manager and head of Clinical Operations since May 2013. From October 2007 to May 2013, Ms. Shigezumi served as a Clinical Program Manager for a number of biotech firms in the Bay Area where she was responsible for multiple global and national studies from phases I to III. Just before joining Virobay, Ms. Shigezumi consulted for Advanced Clinical between November 2011 and May 2013. From March 2011 to September 2011, Ms. Shigezumi served as Clinical Research Manager at Theravance, Inc., where she oversaw two phase II national gastroenterology trials. From May 2010 to February 2011, Ms. Shigezumi served as Clinical Trial Manager at S*Bio Pte. LTD, where she managed a team of eight clinical research associates in several phase I and II U.S. oncology trials. From August 2009 to February 2010, Ms. Shigezumi served as Clinical Trial Manager at OxiGENE, Inc., where she was responsible for five phase I, II and III global oncology and ophthalmology trials. Prior to her employment at OxiGene, Ms. Shigezumi consulted at Pharmacyclics then Cytokinetics between October 2007 and June 2009. During October 1995 and April 2007, Ms. Shigezumi served as Senior Professional Healthcare Representative at Pfizer, Inc., where she served as lead project liaison for a number of phase III and IV studies on multiple disease states. Between her 12 years at Pfizer and Pharmacyclics consultation, Ms. Shigezumi enrolled in the University of California Santa Cruz Extension for clinical trial management. Years before, she received a Bachelor of Arts in biology (human physiology) and a Master in Public Administration (healthcare policies) from San Francisco State University.

Petra Kempf
Office Management and Web Design

Petra Kempf
Office Management and Web Design

At Virobay, Petra is responsible for office management, web design and communication. Petra has 20 years of pharmaceutical industry experience working for Roche, in both Europe and in the US, where she held various positions in pharmaceutical marketing, research, communication and public affairs, as well as site informatics. Petra holds a degree in Business Administration.